{
    "nct_id": "NCT05806814",
    "official_title": "Pilot Trial to Investigate Immune Response to an Extended Course of Sipuleucel-T Immunotherapy in Patients With Metastatic Castration-resistant Prostate Cancer (OU-SCC-EXCITE)",
    "inclusion_criteria": "1. Men ≥ 18 years of age\n2. Prostate cancer with history of metastasis\n3. Candidates for Sipuleucel-T treatment are defined as those with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n5. Life expectancy of ≥ 6 months\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Previously received Sipuleucel-T (Provenge®)\n2. Known malignancies other than prostate cancer likely to require treatment within 6 months following registration\n3. A requirement for systemic immunosuppressive therapy (>10mg Prednisone daily or equivalent)\n4. A history of allergic reactions attributed to compounds of similar chemical or biologic composition to Sipuleucel-T or GM-CSF\n5. Any infection requiring antibiotic therapy within 1 week prior to registration",
    "miscellaneous_criteria": ""
}